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ABSTRACT 
Cases of vaccine-associated paralytic poliomyelitis (VAPP) continued 
increasingly from 2010-2019 in the world. Oral polio vaccine (OPV) is the live 
attenuated virus-based vaccine that could genetically revert to neurovirulent 
during the vaccine production process or when the virus replicates in the 
human body. The poliovirus neurovirulence is determined by the UTR-5’ region 
and VP1 coding region. UTR-5’ played a role in protein translation and VP1 was 
responsible for the immunogenicity of the virus. Some reported mutations in 
UTR-5’ and VP1 could affect the neurovirulence of poliovirus. In this study, we 
analyzed the genetic stability of the UTR-5’ and VP1 in the bulk of OPV types -1 
and -3 produced in 2010 - 2019. The results of the analysis of UTR-5’ sequences 
in Sabin strain types-1 and -3 and VP1 sequences on Sabin virus type 1 did 
not show any mutations. Meanwhile, the VP1 sequences in Sabin strain type 3 
showed nucleotide mutation C2493U that caused the substitution amino acid 
Thr6Ile amino acid in all samples of the type 3 bulk polio test. Based on the 
results of in silico analysis, this mutation in VP1 did not contribute significantly 
to the neurovirulence of the virus.
ABSTRAK 
Kasus lumpuh layu sebagai kejadian ikutan paska imunisasi vaksin oral polio 
(VOP) atau vaccine-associated paralytic poliomyelitis (VAPP) di dunia terus 
bertambah dari tahun 2010-2019. Vaksin ini merupakan vaksin berbasis 
virus hidup yang dilemahkan yang secara genetik dapat kembali menjadi 
neurovirulen selama proses produksi vaksin atau saat virus bereplikasi dalam 
tubuh manusia. Sifat neurovirulensi virus polio ditentukan oleh daerah UTR-5’ 
yang berperan dalam proses translasi protein dan VP1 yang bertanggungjawab 
dalam imunogenisitas virus. Pada penelitian ini dilakukan analisis stabilitas 
genetik daerah UTR-5’ dan VP1 pada bulk VOP tipe -1 dan -3 tahun 2010 - 
2019 yang mempengaruhi neurovirulensi virus. Hasil analisis sekuen UTR-
5’ pada virus Sabin tipe-1 dan -3 serta sekuen VP1 pada virus Sabin tipe 1 
tidak menunjukkan adanya mutasi. Sementara sekuen VP1 pada Sabin tipe 3 
menunjukkan adanya mutasi nukleotida C2493U yang menyebabkan subtitusi 
asam amino Thr6Ile yang ditemukan pada seluruh sampel uji bulk polio tipe 
3. Berdasarkan hasil analisis in silico, mutasi pada VP1 ini tidak berkontribusi 
bermakna terhadap neurovirulensi virus.  
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INTRODUCTION
The oral polio vaccine (OPV) is the 
major vaccine used in polio eradication 
programs. The advantages of OPV 
chosen by many countries for polio 
eradication, such as easy administration, 
able to increase intestinal immunity to 
inhibit the replication of poliovirus in 
the gastrointestinal tract, and low cost. 
However, the weakness of using this 
live-attenuated vaccine is the change 
in the virulence of the Sabin strain that 
causes vaccine-associated paralysis 
poliomyelitis (VAPP) cases. Although it is 
very rare with an estimated 2.9-4.7 cases 
per million births.1 The epidemiological 
study of VAPP by Platt et al.1 reported 
that the trend of VAPP increases among 
countries. Approximately 90% of VAPP 
cases globally occur in low-middle 
income countries in South-East Asia, 
Africa, Western Pacific, and Eastern 
Mediterranean. However, data and 
publications in these area are low. World 
Health Organization (WHO) reported 
that VAPP cases in 2018-2019 occurred 
in 5 countries, namely Argentina, Iran, 
Egypt, Philippines, and Tunisia. It was 
also reported that VAPP cases associated 
with immunocompromised individuals 
vaccinated against OPV continued 
to increase by 66% from 2010-2019.2 
Although OPV plays a major role in polio 
eradication, on the other hand, OPV 
remains become problem as long as the 
use of OPV continues. Neurovirulence 
changes of the Sabin strain are caused 
by mutations that occur during virus 
passages in vaccine production and virus 
replication in the human gut.3,4
Factors causing VAPP cases were 
the viral factor and the external factor. 
The viral factor associated with VAPP 
cases is the unstable RNA genome of the 
Sabin strain, causing nucleotide changes 
that can increase the neurovirulence of 
the virus. In VAPP cases, it turned out 
that mutations did not only occur in 
attenuating nucleotides but could occur 
at other nucleotide positions in UTR-5’ 
or in other genes or regions of the viral 
genome. Taherkhani et al.5 reported that 
mutations at nt 264 and 559 in UTR-5’ led 
to changes in neurovirulence of vaccine 
viruses. In addition, the study conducted 
by Zhang et al.6 reported that amino acid 
substitutions in VP1 protein of VDPV type 
1, such as Ile90Met, Lys99Thr/Glu, and 
Thr106Ala, increased virus virulence. 
Meanwhile, the external factor related to 
VAPP is the host factor. Vaccine-associated 
paralysis poliomyelitis generally 
occurred in people with low immune 
systems, such as immunocompromised 
people. The low host immune system 
caused poliovirus to survive for a long 
time and replicate continuously in the 
gastrointestinal tract.7 It caused the 
accumulation of nucleotide changes that 
can affect the neurovirulence of Sabin 
strain. Because Sabin strain in OPV is 
genetically unstable, neurovirulence 
and vaccine safety monitoring should be 
carried out during vaccine production. 
In Indonesia, vaccine safety monitoring 
correlated to neurovirulence in vaccine 
production was carried out through 
the neurovirulence test in monkey 
(MNVT) and Mutant Analysis by PCR and 
Restriction Enzyme Cleavage (MAPREC) 
(only in bulk OPV type 3).8 The NVT 
in monkey was in vivo method that 
used to monitor viral neurovirulence 
in monkey. The MAPREC method was 
PCR-RFLP method that only monitored 
mutations at attenuating nucleotides 
in UTR-5’, nt 480 (type 1), 481 (type 
2), and 472 (type 3), while mutations 
at other loci of the genome related to 
neurovirulence were not monitored. 
Therefore, in this study, DNA sequencing 
methods were performed on UTR-5’ and 
VP1 to analyze nucleotide changes that 
were not detected by the MAPREC assay 
and associated with the neurovirulence 
phenotype of the NVT assay in monkeys.
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MATERIALS AND METHODS
Ethics statement
This study was approved by the 
Ethics Committee of the Faculty of 
Medicine, University of Indonesia/
Dr. Cipto Mangunkusumo General 
Hospital, Jakarta with the certificate 
of approval no. KET-147/UN2.F1/ETIK/
PPM.00.02/2021 for protocol no. 21-03-
0203.
Samples
Twenty samples used in the study, 
10 samples of OPV bulk type 1 and 10 
samples of OPV bulk type 3, were retained 
sample from 2010 to 2019 that stored at-
70 °C in BPPB, PPPOMN, BPOM. These 
bulk samples have passed MAPREC test 
and neurovirulence tests in monkeys.
PCR primers
The primer set used for 
UTR-5 amplification were U1F 
( 5 ’ - TG C GTG GT TG A A AG C G AC G - 3 ’ ) 
and U1R (5’-ATAACTGTTGAAAT 
TGTACTT-3’) for OPV bulk type 
1; and U3F (5’-CATGTACTTCGAG 
AAGCCTAGTATCGCTC-3’) and 
U3R (5’-AACAAACAAGGGAGTA 
ATTAATCTGATTCA-3’) for OPV bulk 
type 3.9 The primer pairs used for 
VP1 gene amplification were Y7F 
5’-GGGTTTGTGTCAG CCTGTAATGA-3’ 
and Q8R 5’-AAGAGGTCTCTRTTCCA CAT-
3’.10
Extraction of viral RNA
Two hundred microliters of thawed 
frozen-bulk OPV were extracted for viral 
RNA using the PureLink Viral RNA/DNA 
Mini Kit (Invitrogen). The RNA pellet 
was eluted in 50 µL of RNase free water. 
Details of methods used are given in the 
Supplementary Material.
Reverse transcription
Five microliters of extracted RNA 
were reverse transcribed using 200 U 
SuperScript III reverse transcriptase 
(Invitrogen) and 3 µg random primers 
(Invitrogen) in a 20-µL reaction volume 
according to the manufacturer’s 
instructions. Details of methods used are 
given in the Supplementary Material.
PCR and DNA sequencing
Amplification of the UTR-5’ sequence 
and the VP1 gene in this study used 
the i-MAX™ II (INtRON) kit in a 35-µL 
reaction volume. Details of methods 
used are given in the Supplementary 
Material. The PCR product purification 
and sequencing procedures were 
carried out by PT Genetics Science. The 
DNA sequencing process is carried out in 
two reactions using forward and reverse 
primers.
Mutation analysis and amino acid 
change
Bidirectional sequences that 
obtained from DNA sequencing were 
analyzed using BioEdit.11,12 Overlap 
sequences were analyzed and edited 
using SeqScape v2.7 (Applied Biosystems) 
to generate consensus sequences.13 The 
consensus sequences were compared 
to the reference sequences Sabin type 1 
(accession number: AY184219) and Sabin 
type 3 (accession number: AY184221). 
The nucleotide sequences of VP1 were 
translated into amino acid sequences 
using BioEdit. Alignment of the sample 
VP1 amino acid sequence with the 
Sabin reference strain VP1 amino acid 
sequence was performed with multiple 
alignment ClustalW.
Protein conformation
The three-dimensional conformation 
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of the VP1 protein from samples 
undergoing amino acid sequence changes 
were analyzed using the Robetta web 
server (https://robetta.bakerlab.org/).14 
The protein conformational model was 
validated using the Ramachandran Plot 
(https://zlab.umassmed.edu).15 The VP1 
protein structure of OPV bulk sample 
was aligned with VP1 protein structure 
of reference strain using PyMol software.
Phylogenetic analysis
Phylogenetic trees were constructed 
from VP1 coding region sequences 
using Neighbor Joining method in 
Mega X version 7.0.16 The evolutionary 
distances were estimated using Tamura-
Nei method for UTR-5’ and Jones-
Taylor-Thornton (JTT) model for VP1. 
To construct phylogenetic tree of OPV 
bulk, this study used reference Sabin, 
wild-type, attenuated-type and VAPP/




Phylogenetic investigations based 
on the UTR-5’ sequence (FIGUEE 1.A.) 
showed that all bulks of OPV type 1 had 
closest relationship to the reference strain 
Sabin 1 and VAPP isolates from Nigeria, 
India, US, Taiwan, Greece, and China. 
Meanwhile, phylogenetic investigations 
based on the VP1 coding region (FIGURE 
1.B.) showed that all bulks of OPV type 
1 had closest relationship with the 
strain reference Sabin 1 and VAPP/VDPV 
isolates from Nigeria, India, US, Taiwan, 
Greece, China, Russia, and UK. 
FIGURE 1. The phylogenetic tree of OPV bulk type 1 based on UTR-5’ sequence (A) 
and amino acid sequences of VP1 (B). The samples of OVP bulk type 
1 with black parallelogram, attenuated strains with black circle, wild-
type poliovirus strains with black rectangles and VDVP/VAPP strains 
with black triangles. 
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Phylogenetic investigations of bulks 
of OPV type 3 based on UTR-5 sequences 
(FIGURE 2.A.) showed that all samples 
had closest relationship to reference 
strain Sabin 3 and other attenuated 
strains, ZhongIII2 and Leon 12 a1b as seed 
viruses used in OPV type 3 production. 
In addition, they were closely related to 
Sabin-like strain from Nigeria and VAPP 
strains from China as well. The VP1 gene 
phylogenetic tree (FIGURE 2.B.) showed 
that bulks of OPV type 3 were closely 
related to Sabin 3, attenuated strain P3/
Leon12 a1b, and VAPP strains in US, 
Nigeria, and UK. In the VP1 phylogenetic 
tree, the bulks of OPV type 3 were in a 
different clade from ZhongIII2.
FIGURE 2. The phylogenetic tree of OPV bulk type 3 based on UTR-5’ sequence (A) 
and amino acid sequences of VP1 (B). The samples of OVP bulk type 3 
with black parallelogram, attenuated strains with a black circle, wild-
type poliovirus strains with black rectangles and VDVP/VAPP strains 
with black triangles.
Mutation analysis and amino acid 
changes
To identify mutations in UTR-5’ 
sequences, the obtained UTR-5’ sequences 
from ten bulk samples of type 1 (231-
690 bp) and ten bulk samples of OPV 
type 3 (267-643 bp) were aligned with 
UTR-5’ sequences from reference strain 
Sabin 1 and 3, respectively. Analysis 
of UTR-5’ sequences of OPV bulk polio 
types 1 and 3 showed those sequences 
similar to reference strain Sabin 1 and 3, 
respectively. Analysis of VP1 amino acid 
sequences (300 amino acids) of twenty 
bulk samples of OPV bulk type 1 and 3 
showed those of OPV bulk type 1 similar 
to reference strain Sabin 1 (TABLE 1). 
On the other hand, VP1 OPV bulk type 3 
differed from reference strain Sabin 3 at 
amino acid position six of VP1, Thr6Ile, as 
a missense mutation (TABLE 1). Sequence 
divergence in VP1 of 20 samples of bulk 
polio types 1 and 3 < 1% so these are still 
categorized as Sabin strain.
J Med Sci, Volume 53, Number 4, 2021 October:
TABLE1. Alignment of VP1 amino acids from 20 bulk samples of OPV type 1 and 
3 produced in 2010-2019 at the hotspot of VP1 amino acid changes 
related to poliovirus virulence.
Strain
Amino acid position in VP1 protein
         906,17,18          996,17,18   1066,17,18                           1346
Sabin 1* CVAIITVDNSASTKNKDKLFTVWKIT   TYSRFDMEFTFVV
Mahoney** ..T.M....P...T......A.....   ........L....
S1-1 ..........................   .............
S1-2 ..........................   .............
S1-3 ..........................   .............
S1-4 ..........................   .............
S1-5 ..........................   .............
S1-6 ..........................   .............
S1-7 ..........................   .............
S1-8 ..........................   .............
S1-9 ..........................   .............
S1-10 ..........................   .............
     67,17                         5419                        10519
Sabin 3* DLTSEVAQ     TNPLAP     AQKLFAMWR
P/Leon** ..I.....     ......     .........
S3-1 ..I.....     ......     .........
S3-2 ..I.....     ......     .........
S3-3 ..I.....     ......     .........
S3-4 ..I.....     ......     .........
S3-5 ..I.....     ......     .........
S3-6 ..I.....     ......     .........
S3-7 ..I.....     ......     .........
S3-8 ..I.....     ......     .........
S3-9 ..I.....     ......     .........
S3-10 ..I.....     ......     .........
Note: *reference strain of OPV, **wild-type poliovirus strain. The dot (.) represents 
the consensus of the amino acids of bulk polio that are similar to the 
reference strain Sabin.
Protein conformation
The amino acid substitution that 
occurred from this missense mutation 
was analyzed for the three-dimensional 
structure of the VP1 protein with the 
Robetta web server (https://robetta.
bakerlab.org/). The 3D protein model 
VP1 of samples of OPV bulk type 3 
and the reference strain Sabin 3 were 
validated by Ramachandran plots. The 
Ramachandran plot of the VP1 protein 
model of OPV bulk type 3 (FIGURE 3.A.) 
showed that there were 255 amino acids 
(97.32%) in the favored region, six amino 
acids (2.29%) in the allowed region, and 
one amino acid (0.38%) in the outlier’s 
region. Meanwhile, the Ramachandran 
plot of the VP1 protein model of reference 
strain Sabin 3 (FIGURE 3.B.) showed that 
there were 253 amino acids (96.57%) in 
the favored region, eight amino acids 
(3.05%) in the allowed region, and one 
amino acid (0.38%) in the outlier’s region. 
These results indicate the good quality of 
the protein model. 
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FIGURE 3. A:Ramachandran plot of VP1 protein model of OPV bulk type 3. 
B:Ramachandran plot of VP1 protein model of reference strain Sabin 3.
The result of overlapping VP1 
protein structures from the bulk polio 
type 3 and VP1 Sabin 3 (FIGURE 4.) 
showed that Thr6Ile substitution caused 
a conformational change in the VP1 
protein. The conformational change seen 
in the folding of the VP1 protein of OPV 
bulk type 3 tended to close compared to 
Sabin 3. These conformational change in 
the N-terminal region was suspected not 
affect the function of VP1 related to the 
interaction with the CD155 receptor or 
the function of immunogenicity.
FIGURE 4. Overlapping of VP1 protein models of 
OPV bulk type 3 and Sabin 3 using PyMol 
(https://pymol.org/2/). The VP1 protein 
model of OPV bulk type 3 shown as 
blue line. The VP1 protein model of the 
reference strain Sabin 3 shown as green 
line. Thr6Ile substitution is marked with a 
purple asterisk.
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DISCUSSION
The phylogenetic tree of bulk OPV 
types 1 and 3 based on UTR-5’ and VP1 
showed that the bulk of OPV types 1 and 
3 were close related to the reference 
strain (Sabin 1 and Sabin 3). These also 
showed that VAPP strains from various 
countries have close relationship with 
OPV bulk types 1 and 3. The VAPP strain, 
which was in the same clade as the bulk 
polio type 1 and 3 samples, did not have 
back mutations at attenuation points of 
480 (type 1) or 472 (type 3). Therefore, 
the occurrence of VAPP might be due to 
mutations at other positions in UTR-5’ 
or mutations in other genes that affect 
poliovirus neurovirulence.
Mutations in UTR-5’ region could 
affect the regulation of protein translation 
and RNA replication of poliovirus. Several 
studies reported changes in UTR-5’ 
region causing changes in the secondary 
structure and affinity for cellular factors 
that affect protein translation and viral 
replication.20-22 Protein translation and 
viral replication are important factors 
that influence viral virulence properties. 
The translational activity of the virus 
is closely related to the level of viral 
replication.21 In this study, the UTR-5’ 
sequences from all bulks of OPV types 1 
and 3 had no nucleotide changes. It also 
states that bulks of OPV types 1 and 3 
had no reverse mutation in attenuating 
nucleotides, A480G (type 1) and U472C 
(type 3), while the secondary data from 
the MAPREC test on bulk polio type 3 used 
in this study reported the accumulation 
of the 472C revertant mutant with a 
proportion of <1%. It was the limitation 
of Sanger DNA sequencing method which 
only determine the nucleotide base 
sequence of nucleic acid/gene/genome 
sequences but cannot detect a mixture 
of sequence variants with a proportion 
of <1% due to background noise 
generated by the polymerase enzyme 
during the PCR process. However, 
there is a high-throughput and accurate 
sequencing method, Massively Parallel 
Sequencing or deep sequencing can 
analyze quasispecies of viruses that can 
identify the very small number of viral 
mutants (<1%),23 so it could be developed 
to quantify reverent mutations at the 
attenuation point.
Mutations in the VP1 gene could 
affect poliovirus neurovirulence as 
well because VP1 contributes greatly 
to antigenic neutralization sites and as 
a constituent of the outer capsid that 
interacts with the external environment 
and host cells.24 This study showed that 
all bulks of OPV type 1 had no change 
in the nucleotide sequences of the VP1 
gene. Meanwhile, all bulks of OPV type 
3 samples had C2493U mutation in VP1 
gene. The results of alignment of amino 
acid sequence of VP1 in TABLE 1, showed 
C2493U mutation is a missense mutation, 
caused change in amino acid position 
six from threonine to isoleucine in VP1 
protein of bulk OPV type 3. The results 
of this study were in line with the study 
conducted by Neverov and Chumakov25 
which found an accumulation of the 
C2493U mutation in OPV type 3 analyzed 
by the Massively Parallel Sequencing 
method. In addition to the research 
conducted by Deng et al.3 also reported 
an accumulation of C2493U mutations 
in Pfizer and Zhong-3 strains of 13% 
and 99%, respectively, using the deep 
sequencing method.
The in vitro study showed that the 
C2493U mutation in VP1 correlated with 
a partial loss of attenuation properties 
of the Sabin 3.26 In addition, it was also 
reported that the Sabin 3 strain containing 
the 2493U mutation usually failed the 
neurovirulence test of transgenic mice 
with the CD155 receptor but passed the 
NVT test in monkeys.27 This is in line with 
the secondary data from the NVT test in 
monkeys for the ten bulk polio type 3 
samples used in this study, which were 
not neurovirulent in monkeys. Based on 
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that, the C2493U mutation caused a non-
significant increase in neurovirulence of 
Sabin 3 in vivo. It did not cause paralytic 
polio in monkeys.
The three-dimensional conformational 
analysis of the VP1 protein model in 
silico in figure 4. showed that there is 
a change in the conformation of the 
protein VP1 bulk polio type 3 with 
Thr6Ile substitution which tends closer 
than the conformational protein VP1 
of the reference strain Sabin 3. This 
change could be due to differences in 
the properties of the acid. polar amino 
threonine with a hydroxyl side group 
and isoleucine amino acid which is 
nonpolar with a hydrocarbon side 
group. The conformational stability of 
the protein can be affected by a single 
amino acid substitution.28 However, 
in this study, analysis of the protein 
binding of VP1 of bulk polio type 3 
with Thr6Ile substitution for the CD155 
receptor was not carried out so that the 
effect of changes in confirmation of VP1 
protein on the affinity of the receptor is 
unknown. The study conducted by Wien 
et al.29 reported that the amino acid 
position 6 is in the N-terminal region 
of VP1 and is located within the virion 
which is associated with the terminal 
regions of other capsid proteins to form 
a network that plays a role in the stability 
of virion assembly. Tatem26 explained 
that upon attachment of the virus to the 
host cell, the N-terminal region of VP1 
is externalized from within the virion, 
which then exposes the N-terminal 
into the cell required for attachment 
to liposomes. Studies conducted by 
Kirkegaard30 also found that deletions in 
the N-terminal VP1 caused the failure of 
the release of viral RNA from the capsid 
into the host cell. Based on the results of 
these studies, it can be stated that the N 
terminal in VP1 plays a role in the entry 
of the virus into the cell, does not play a 
role in the interaction of the virus with 
the host cell receptor.
CONCLUSION
In this study we found that UTR-5’ 
sequence of Sabin strains of type -1 and 
-3 in OPV bulk was conserved. The VP1 
gene from Sabin type 1 strain in bulk 
OPV was more conserve than Sabin type 
3 in bulk OPV. Based on 3D analysis, 
mutation of Ile6Thr in VP1 of OPV bulk 
Sabin type 3 is predicted to not give any 
significant effect to viral neurovirulence. 
However, it is necessary to consider to 
do genetic stability monitoring of Sabin 
during OPV production process.
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